Log in

Relevant bibliographies by topics / Insulin and non insulin / Journal articles

To see the other types of publications on this topic, follow the link: Insulin and non insulin.

Journal articles on the topic 'Insulin and non insulin'

Author: Grafiati

Published: 2 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Insulin and non insulin.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Pandya, Maitrey, and Miral Damani. "NEUROPHYSIOLOGICAL CHANGES IN PERSON WITH INSULIN DEPENDENT AND NON INSULIN DEPENDENT DIABETES MELLITUS." International Journal of Physiotherapy and Research 7, no. 2 (2019): 3011–15. http://dx.doi.org/10.16965/ijpr.2019.102.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Taylor, R. "Insulin for the non-insulin dependent?" BMJ 296, no. 6628 (1988): 1015–16. http://dx.doi.org/10.1136/bmj.296.6628.1015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

MacPherson, J. N. "Insulin for the non-insulin dependent?" BMJ 296, no. 6633 (1988): 1401. http://dx.doi.org/10.1136/bmj.296.6633.1401.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Holman, R. R. "Insulin for the non-insulin dependent?" BMJ 296, no. 6634 (1988): 1469–70. http://dx.doi.org/10.1136/bmj.296.6634.1469-c.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Diaz, J. L., and T. J. Wilkin. "Effect of iodination site on binding of radiolabeled ligand by insulin antibodies and insulin autoantibodies." Clinical Chemistry 34, no. 2 (1988): 356–59. http://dx.doi.org/10.1093/clinchem/34.2.356.

Full text

Abstract:

Abstract Four human insulins and four porcine insulins, each monoiodinated to the same specific activity at one of the four tyrosine residues (A14, A19, B16, B26) and purified by reversed-phase liquid chromatography, were tested in a radiobinding assay against a panel of insulin-antibody (IA)-positive sera from 10 insulin-treated diabetics and insulin-autoantibody-positive (IAA) sera from 10 nondiabetics. Of the 10 IAA-positive sera, five were fully cross reactive with both insulin species, and five were specific for human insulin. The rank order of binding of sera with the four ligands from e

APA, Harvard, Vancouver, ISO, and other styles

6

Cerasi, Erol. "Insulin resistance, insulin deficiency, and non-insulin-dependent diabetes mellitus." Diabetes Research and Clinical Practice 14 (January 1991): S37—S45. http://dx.doi.org/10.1016/0168-8227(91)90006-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Ingrasciotta, Ylenia, Giacomo Vitturi, and Gianluca Trifirò. "Pharmacological and Benefit-Risk Profile of Once-Weekly Basal Insulin Administration (Icodec): Addressing Patients’ Unmet Needs and Exploring Future Applications." Journal of Clinical Medicine 13, no. 7 (2024): 2113. http://dx.doi.org/10.3390/jcm13072113.

Full text

Abstract:

Diabetes mellitus (DM) is a chronic metabolic disease affecting over 500 million people worldwide, which leads to severe complications and to millions of deaths yearly. When therapeutic goals are not reached with diet, physical activity, or non-insulin drugs, starting/adding insulin treatment is recommended by international guidelines. A novel recombinant insulin is icodec, a once-weekly insulin that successfully completed phase III trials and that has recently obtained the marketing authorization approval from the European Medicines Agency. This narrative review aims to assess icodec pharmaco

APA, Harvard, Vancouver, ISO, and other styles

8

Bereda, Gudisa. "Role of Insulin: Perspectives." Diabetes and Islet Biology 5, no. 1 (2022): 01–06. http://dx.doi.org/10.31579/2641-8975/030.

Full text

Abstract:

The pancreas in a non-diabetic patient invariably produces a lesser quantum of insulin (basal production). Insulin furnishes glucose homeostasis by keeping the plasma glucose worth in an optimum class throughout the day. It assists transport blood glucose into the body cells where the glucose is metabolized to generate energy. Regular insulin is inserted pre-meal to abrupt the postprandial ascend in glucose levels. It figures hexamers after insertion into the subcutaneous space sluggishing its absorption. Ultra-fast acting commences to act 4-7 minutes before regular apidra and lasts for around

APA, Harvard, Vancouver, ISO, and other styles

9

Temple, RosemaryC, StephenD Luzio, AnneroseE Schneider, et al. "INSULIN DEFICIENCY IN NON-INSULIN-DEPENDENT DIABETES." Lancet 333, no. 8633 (1989): 293–95. http://dx.doi.org/10.1016/s0140-6736(89)91306-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Scott, R. S., D. R. Mason, F. J. M. Iris, and J. R. Bremer. "Insulin deficiency in non-insulin-dependent diabetics." Diabetes Research and Clinical Practice 2, no. 6 (1986): 359–64. http://dx.doi.org/10.1016/s0168-8227(86)80073-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Garrow, J. S. "Points: Insulin for the non-insulin dependent?" BMJ 296, no. 6635 (1988): 1540. http://dx.doi.org/10.1136/bmj.296.6635.1540-f.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

de Neeling, J. N. "Insulin resistance and non-insulin-dependent diabetes." JAMA: The Journal of the American Medical Association 274, no. 18 (1995): 1426b—1426. http://dx.doi.org/10.1001/jama.274.18.1426b.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

de Neeling, J. Nico D. "Insulin Resistance and Non—insulin-dependent Diabetes." JAMA: The Journal of the American Medical Association 274, no. 18 (1995): 1426. http://dx.doi.org/10.1001/jama.1995.03530180020016.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Mikhail, Nasser. "Insulin U-500, the Practical Solution for the treatment of Patients with High Insulin Requirements." Current Diabetes Reviews 17, no. 1 (2020): 26–29. http://dx.doi.org/10.2174/1573399816666200408084614.

Full text

Abstract:

Background: Human regular insulin 500 (U-500) is 5 five times more concentrated than the traditional regular human insulin (U-100). Thus, every 1 ml of U-500 contains 500 units of insulin as opposed to 100 units/ml with most types of insulin. Methods: Review of all the relevant clinical studies related to insulin U-500 until February 12, 2020. Results: Insulin U-500 is indicated in patients with type 2 diabetes who require more than 200 units of insulin per day. Insulin U-500 has both prandial and basal actions, and can be injected as monotherapy in a convenient twice-daily regimen. Available

APA, Harvard, Vancouver, ISO, and other styles

15

Taylor, M. Joan, Krishan P. Chauhan, and Tarsem S. Sahota. "Glucose lowering strategies with insulin." British Journal of Diabetes 19, no. 2 (2019): 124–30. http://dx.doi.org/10.15277/bjd.2019.228.

Full text

Abstract:

People with type 1 diabetes must use insulin and a large fraction of those with type 2 condition also do so. Many therefore struggle with the unpredictable balancing of insulin dose with calorie intake and utility. A healthy pancreas makes meticulous adjustment on a continuous basis that present therapeutic insulin administration cannot match. However, much progress has been made to make it simpler to inject both background and fast-acting boost insulins with a view to better mimicking normal pancreatic output. The present fast insulins are reviewed with accent on the primary amino acid struct

APA, Harvard, Vancouver, ISO, and other styles

16

Arnold, Lindsay M., Darcie L. Keller, and Toyin S. Tofade. "Hyperglycemia Management in Non-critically Ill Hospitalized Patients." Journal of Pharmacy Practice 22, no. 5 (2009): 467–77. http://dx.doi.org/10.1177/0897190008330198.

Full text

Abstract:

There is increasing evidence demonstrating negative consequences and poor clinical outcomes associated with untreated hyperglycemia in hospitalized patients. Data in specific patient populations, primarily critically ill patients, demonstrate improved patient outcomes with tight glycemic control. To date, no clear evidence exists to determine optimal glycemic targets in non-critically ill patients; however, experts agree that better glycemic control in hospitalized patients is warranted. Glycemic control is complicated by numerous factors in hospitalized patients including increased circulatin

APA, Harvard, Vancouver, ISO, and other styles

17

Thomas, Meenu, Prithpal Singh Matreja, Jedidiah Solomon Prakash, and Naveen Kumar Singh. "Insulin Icodec: A Silver Lining to the Diabetic Cloud." International Journal of Human and Health Sciences (IJHHS) 8, no. 1 (2024): 15. http://dx.doi.org/10.31344/ijhhs.v8i1.615.

Full text

Abstract:

Adequate glycaemic control is the sole way to circumvent the microvascular and macrovascular complications of diabetes mellitus. Currently, available treatment options include oral hypoglycaemic agents and insulin. Oral antidiabetic drugs are often limited in their efficacy to reduce HbA1c beyond 1-2%. It is insulin alone that can reduce HbA1c exceptionally and keep it near normal. The benchmark route of insulin administration is subcutaneous injections. However, subcutaneous insulin administration accompanies issues like pain at injection site, needle phobia, lipodystrophy, peripheral hyperin

APA, Harvard, Vancouver, ISO, and other styles

18

Savoy, L. A., R. M. L. Jones, S. Pochon, et al. "Identification by fast atom bombardment mass spectrometry of insulin fragments produced by insulin proteinase." Biochemical Journal 249, no. 1 (1988): 215–22. http://dx.doi.org/10.1042/bj2490215.

Full text

Abstract:

We describe the isolation by reversed-phase h.p.l.c. of a number of products of the degradation of insulin by insulin proteinase and their direct analysis by fast atom bombardment mass spectrometry (f.a.b.-m.s.). Various semisynthetically labelled insulins were used, including [[2H2]GlyA1]insulin and [18O]LysB29]insulin. The results obtained confirm and extend the results obtained by non-mass-spectrometric methods [Davies, Muir, Rose & Offord (1988) Biochem. J. 249, 209-214, and papers cited therein]. Cleavage sites were identified between positions A13-A14, A14-A15, B9-B10, B13-B14, B24-B

APA, Harvard, Vancouver, ISO, and other styles

19

Ewen, Margaret, Huibert-Jan Joosse, David Beran, and Richard Laing. "Insulin prices, availability and affordability in 13 low-income and middle-income countries." BMJ Global Health 4, no. 3 (2019): e001410. http://dx.doi.org/10.1136/bmjgh-2019-001410.

Full text

Abstract:

IntroductionGlobally, one in two people needing insulin lack access. High prices and poor availability are thought to be key contributors to poor insulin access. However, few studies have assessed the availability, price and affordability of different insulin types in low-income and middle-income countries in a systematic way.MethodsIn 2016, 15 insulin price and availability surveys were undertaken (using an adaptation of the WHO/Health Action International medicine price and availability measurement methodology) in Brazil, China (Hubei and Shaanxi Provinces), Ethiopia, Ghana, India (Haryana a

APA, Harvard, Vancouver, ISO, and other styles

20

Warraich, Haider J., Hasan K. Siddiqi, Diane G. Li, Jeroen van Meijgaard, and Muthiah Vaduganathan. "Pharmacy and neighborhood-level variation in cash price of diabetes medications in the United States." PLOS ONE 18, no. 12 (2023): e0294164. http://dx.doi.org/10.1371/journal.pone.0294164.

Full text

Abstract:

Background Diabetes medications place significant financial burden on patients but less is known about factors affecting cost variation. Objective To examine pharmacy and neighborhood factors associated with cost variation for diabetes drugs in the US. Research design, subjects and measures We used all-payer US pharmacy data from 45,874 chain and independent pharmacies reflecting 7,073,909 deidentified claims. We divided diabetes drugs into insulins, non-insulin generic medications, and brand name medications. Generalized linear models, stratified by pharmacy type, identified pharmacy and neig

APA, Harvard, Vancouver, ISO, and other styles

21

Cradock, Sue. "Non-insulin dependent." Primary Health Care 3, no. 5 (1993): 16–19. http://dx.doi.org/10.7748/phc.3.5.16.s12.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Jahromi, Abdolreza Sotoodeh, and Zhila Rahmanian. "25: ASSOCIATION OF SERUM GAMMA- INTERFERON AND IL-10 CONCENTRATIONS WITH INSULIN RESISTANCE IN MAJOR THALASSEMIA PATIENTS." BMJ Open 7, Suppl 1 (2017): bmjopen—2016–015415.25. http://dx.doi.org/10.1136/bmjopen-2016-015415.25.

Full text

Abstract:

Background and aims:Thalassemia is one of the most prevalent hematologic disorders worldwide. Thalassemia is the most common inherited anemia and genetic disease. Diabetes mellitus and insulin resistance is one of the major endocrine problems in major thalassemia patients. This study was done to evaluate the association of serum γ- interferon and IL-10 concentrations with insulin resistance in splenectomized and non-splenectomized major thalassemia patients.Methods:193 thalassemia patients with rang of years old participated in this study. IFN-γ and IL-10 levels were measured using ELISA metho

APA, Harvard, Vancouver, ISO, and other styles

23

Pandya, Maitrey, and Miral Damani. "NEUROPHYSIOLOGICAL CHANGES IN CONTEXT TO DURATION OF EXPOSURE IN INSULIN DEPENDENT AND NON INSULIN DEPENDENT DIABETES MELLITUS." International Journal of Physiotherapy and Research 5, no. 2 (2017): 1902–5. http://dx.doi.org/10.16965/ijpr.2016.178.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Olefsky, Jerrold M. "Insulin resistance in non-insulin-dependent diabetes mellitus." Current Opinion in Endocrinology and Diabetes 2, no. 4 (1995): 290–99. http://dx.doi.org/10.1097/00060793-199508000-00003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Alzaid, A. A. "Insulin resistance in non-insulin-dependent diabetes mellitus." Acta Diabetologica 33, no. 2 (1996): 87–99. http://dx.doi.org/10.1007/s005920050013.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Alzaid, A. A. "Insulin resistance in non-insulin-dependent diabetes mellitus." Acta Diabetologica 33, no. 2 (1996): 87–99. http://dx.doi.org/10.1007/bf00569416.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Gerich, John. "Insulin Resistance and Non—insulin-dependent Diabetes-Reply." JAMA: The Journal of the American Medical Association 274, no. 18 (1995): 1426. http://dx.doi.org/10.1001/jama.1995.03530180020017.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Fisher, Miles. "Series: Cardiovascular outcome trials for diabetes drugs Degludec and DEVOTE." British Journal of Diabetes 21, no. 1 (2021): 113–15. http://dx.doi.org/10.15277/bjd.2021.302.

Full text

Abstract:

DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec versus Insulin Glargine in Patients with Type 2 Diabetes at High Risk of Cardio-vascular Events) was an FDA-mandated cardiovascular outcome trial and was the first – and at present the only – completed trial comparing two insulins. DEVOTE compared insulin degludec and insulin glargine (U100) in 7,637 people with type 2 diabetes with established cardiovascular disease, chronic kidney disease, or both, and older diabetic patients with increased cardiovascular risk. DEVOTE demonstrated non-inferiority for major cardiovascular event

APA, Harvard, Vancouver, ISO, and other styles

29

Vlasenko, І. О., L. L. Davtian, and V. V. Hladyshev. "Modern strategies of alternative insulin delivery systems." Zaporozhye Medical Journal 25, no. 3 (2023): 262–69. http://dx.doi.org/10.14739/2310-1210.2023.3.274844.

Full text

Abstract:

There are barriers to initiation, use or intensification of insulin therapy for patients with diabetes. A non-invasive therapeutic approach in insulin therapy should overcome these barriers. The development of alternative methods of insulin delivery is a complex task of fundamental medicine and pharmacy. The availability of oral / nasal insulin helps millions of people with diabetes avoid daily burden of subcutaneous insulin injections. The aim of the work was to study the current state of the latest developments in alternative routes of insulin delivery, their technology, and clinical trials.

APA, Harvard, Vancouver, ISO, and other styles

30

Annastya Devie Oktavia and Abi Muhlisin. "Insulin treatment adherence in type 2 diabetes mellitus patients: Literature review." Open Access Research Journal of Science and Technology 10, no. 2 (2024): 001–6. http://dx.doi.org/10.53022/oarjst.2024.10.2.0038.

Full text

Abstract:

One of the hallmarks of diabetes, a metabolic disease caused by a lack of secretion, work, or both insulins, is hyperglycemia. Although insulin is the most effective treatment for diabetes mellitus, most patients are reluctant to inject insulin. A problem that can arise from not taking insulin as prescribed at the initial dose is cardiovascular disease, which is a leading cause of morbidity and death in diabetics. The goal is to analyze the administration of insulin therapy in diabetic individuals who receive it. The PICO Strategy method is applied to research topics using populations/problems

APA, Harvard, Vancouver, ISO, and other styles

31

Inman, Taylor R., Erika Plyushko, Nicholas P. Austin, and Jeremy L. Johnson. "The role of basal insulin and GLP-1 receptor agonist combination products in the management of type 2 diabetes." Therapeutic Advances in Endocrinology and Metabolism 9, no. 5 (2018): 151–55. http://dx.doi.org/10.1177/2042018818763698.

Full text

Abstract:

The prevalence of type 2 diabetes necessitates the development of new treatment options to individualize therapy. Basal insulin has been a standard treatment option for years, while glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have grown in use over the past decade due to glucose-lowering efficacy and weight loss potential. There are two new combination injectable products that have recently been approved combining basal insulins with GLP-1 RAs in single pen-injector devices. United States guidelines recently emphasize the option to use combination injectable therapy with GLP-1 RAs an

APA, Harvard, Vancouver, ISO, and other styles

32

Joffe, Bi, I. Segal, Vr Panz, Jr Wing, Fj Raal, and Hc Seftel. "Insulin resistance or insulin deficiency as precursor of non-insulin-dependent diabetes mellitus." Lancet 344, no. 8938 (1994): 1705. http://dx.doi.org/10.1016/s0140-6736(94)90488-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Saudek, Christopher D. "Implantable Insulin Pump vs Multiple-Dose Insulin for Non—Insulin-Dependent Diabetes Mellitus." JAMA 276, no. 16 (1996): 1322. http://dx.doi.org/10.1001/jama.1996.03540160044031.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

WOLFFENBUTTEL, B. H. R., and T. W. VAN HAEFTEN. "Non-insulin dependent diabetes mellitus: defects in insulin secretion." European Journal of Clinical Investigation 23, no. 2 (1993): 69–79. http://dx.doi.org/10.1111/j.1365-2362.1993.tb00743.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Kim, Jongoh, Se Min Kim, Ha Cam Thuy Nguyen, and Maria Jose Redondo. "Therapeutics in pediatric diabetes: Insulin and non-insulin approaches." Pharmacological Research 65, no. 1 (2012): 1–4. http://dx.doi.org/10.1016/j.phrs.2011.08.011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Karam, J. "Reversible Insulin Resistance in Non-Insulin-Dependent Diabetes Mellitus." Hormone and Metabolic Research 28, no. 09 (1996): 440–44. http://dx.doi.org/10.1055/s-2007-979834.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Heine, Robert J. "12 Insulin treatment of non-insulin-dependent diabetes mellitus." Baillière's Clinical Endocrinology and Metabolism 2, no. 2 (1988): 477–92. http://dx.doi.org/10.1016/s0950-351x(88)80044-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Clements, Rex S., David S. H. Bell, Abdel Benbarka, and Stuart A. Capper. "Rapid insulin initiation in non-insulin-dependent diabetes mellitus." American Journal of Medicine 82, no. 3 (1987): 415–20. http://dx.doi.org/10.1016/0002-9343(87)90440-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

TEMPLE, ROSEMARY C., PENELOPE M. S. CLARK, DINESH K. NAGI, ANNEROSE E. SCHNEIDER, JOHN S. YUDKIN, and C. NICHOLAS HALES. "RADIOIMMUNOASSAY MAY OVERESTIMATE INSULIN IN NON-INSULIN-DEPENDENT DIABETICS." Clinical Endocrinology 32, no. 6 (1990): 689–93. http://dx.doi.org/10.1111/j.1365-2265.1990.tb00915.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Jeanrenaud, B., and S. Halimi. "Insulin resistance in non-insulin-dependent diabetes mellitus (NIDDM)." Diabetes Research and Clinical Practice 4 (January 1988): 6–7. http://dx.doi.org/10.1016/0168-8227(88)90004-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Grunstein, H. S., G. A. Smythe, L. H. Storlien, Per Westermark, and Erik Wilander. "NON-INSULIN-DEPENDENT DIABETES." Lancet 326, no. 8446 (1985): 104–5. http://dx.doi.org/10.1016/s0140-6736(85)90212-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Najjar, Sonia M., Raziyeh Abdolahipour, Hilda E. Ghadieh, et al. "Regulation of Insulin Clearance by Non-Esterified Fatty Acids." Biomedicines 10, no. 8 (2022): 1899. http://dx.doi.org/10.3390/biomedicines10081899.

Full text

Abstract:

Insulin stores lipid in adipocytes and prevents lipolysis and the release of non-esterified fatty acids (NEFA). Excessive release of NEFA during sustained energy supply and increase in abdominal adiposity trigger systemic insulin resistance, including in the liver, a major site of insulin clearance. This causes a reduction in insulin clearance as a compensatory mechanism to insulin resistance in obesity. On the other hand, reduced insulin clearance in the liver can cause chronic hyperinsulinemia, followed by downregulation of insulin receptor and insulin resistance. Delineating the cause–effec

APA, Harvard, Vancouver, ISO, and other styles

43

Laurenti, Marcello C., Chiara Dalla Man, Ron T. Varghese, et al. "Insulin Pulse Characteristics and Insulin Action in Non-diabetic Humans." Journal of Clinical Endocrinology & Metabolism 106, no. 6 (2021): 1702–9. http://dx.doi.org/10.1210/clinem/dgab100.

Full text

Abstract:

Abstract Objective Pulsatile insulin secretion is impaired in diseases such as type 2 diabetes that are characterized by insulin resistance. This has led to the suggestion that changes in insulin pulsatility directly impair insulin signaling. We sought to examine the effects of pulse characteristics on insulin action in humans, hypothesizing that a decrease in pulse amplitude or frequency is associated with impaired hepatic insulin action. Methods We studied 29 nondiabetic subjects on two occasions. On 1 occasion, hepatic and peripheral insulin action was measured using a euglycemic clamp. The

APA, Harvard, Vancouver, ISO, and other styles

44

Glinkina, I. V. "Results of the observational program on the use of insulin glargine (Lantus) in combination with oral hypoglycemic agents or prandial insulins for the treatment of type 2 diabetes mellitus in routine clinical practice." Problems of Endocrinology 56, no. 5 (2010): 61–66. http://dx.doi.org/10.14341/probl201056561-66.

Full text

Abstract:

The objective of this observational program was to evaluate the efficiency and safety of insulin glargine used to treat patients with type 2 diabetes mellitus (DM2) who failed to achieve adequate compensation of carbohydrate metabolism during therapy with NPC insulin in combination with oral hypoglycemic agents or prandial insulins. The secondary objective was to estimate satisfaction of physicians with the results of insulin glargine therapy. The open, prospective non-randomized multicentre observational study included 7.334 patients of the mean age 58.3±9.0 years presenting with type 2 diabe

APA, Harvard, Vancouver, ISO, and other styles

45

Christiansen, E. "Insulin secretion, insulin action and non-insulin-dependent glucose uptake in pancreas transplant recipients." Journal of Clinical Endocrinology & Metabolism 79, no. 6 (1994): 1561–69. http://dx.doi.org/10.1210/jc.79.6.1561.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Ferrannini, Ele. "Insulin Resistance versus Insulin Deficiency in Non-Insulin-Dependent Diabetes Mellitus: Problems and Prospects." Endocrine Reviews 19, no. 4 (1998): 477–90. http://dx.doi.org/10.1210/edrv.19.4.0336.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Christiansen, E., A. Tibell, A. Võlund, et al. "Insulin secretion, insulin action and non-insulin-dependent glucose uptake in pancreas transplant recipients." Journal of Clinical Endocrinology & Metabolism 79, no. 6 (1994): 1561–69. http://dx.doi.org/10.1210/jcem.79.6.7989456.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

ROSE, MICHAEL T., YOSHIAKI OBARA, FUMIAKI ITOH, HARUO HASHIMOTO, and YUJI TAKAHASHI. "Non-insulin- and insulin-mediated glucose uptake in dairy cows." Journal of Dairy Research 64, no. 3 (1997): 341–53. http://dx.doi.org/10.1017/s0022029997002215.

Full text

Abstract:

Four mid-lactation Holstein dairy cows (mean milk yield on day of experiments 26·1 kg/d) were used in a series of experiments to establish the contribution of non-insulin-mediated glucose uptake to total glucose uptake at basal insulin concentrations. A secondary objective was to determine whether somatostatin affects the action of infused insulin. In part I of the experiment a primed continuous infusion of [6,6-2H]glucose (45·2 μg/kg per min) was begun at time 0 and continued for 5 h. After 3 h of [6,6-2H]glucose infusion (basal period) a primed continuous infusion of insulin (0·001 i.u./kg p

APA, Harvard, Vancouver, ISO, and other styles

49

Mera, Carlos Andree Cevallos. "Therapeutic Adherence in Patients with Diabetes Mellitus Non-insulin Dependent." International Journal of Psychosocial Rehabilitation 24, no. 5 (2020): 1571–78. http://dx.doi.org/10.37200/ijpr/v24i5/pr201828.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Niwa, Yuko S., and Ryusuke Niwa. "Endocrinology: Non-insulin-producing cells secrete insulin under nutrient shortage." Current Biology 32, no. 8 (2022): R380—R382. http://dx.doi.org/10.1016/j.cub.2022.03.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!